Compass Therapeutics Inc. - Asset Resilience Ratio
Compass Therapeutics Inc. (CMPX) has an Asset Resilience Ratio of 68.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Compass Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Check Compass Therapeutics Inc. (CMPX) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Compass Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Compass Therapeutics Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $139.52 Million | 68.0% |
| Total Liquid Assets | $139.52 Million | 68.00% |
Asset Resilience Insights
- Very High Liquidity: Compass Therapeutics Inc. maintains exceptional liquid asset reserves at 68.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Compass Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Compass Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Compass Therapeutics Inc. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Compass Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 81.18% | $178.26 Million | $219.59 Million | +21.89pp |
| 2024-12-31 | 59.29% | $83.24 Million | $140.40 Million | -22.46pp |
| 2023-12-31 | 81.74% | $128.23 Million | $156.88 Million | +5.78pp |
| 2022-12-31 | 75.97% | $151.66 Million | $199.65 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $153.76 Million | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tum… Read more